Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 327 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Bortezomib, Decitabine, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Pexastimogene Devacirepvec (Pexa Vec), Sorafenib
Biological · Drug
Lead sponsor
SillaJen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Orange, California + 19 more
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, ITMHA, Idarubicin, Fludarabine, Mitoxantrone, Erwinia asparaginase, Sorafenib, G-CSF, Dexrazoxane, Stem Cell Transplant, Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
Drug · Combination Product · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
29 Days to 21 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Madera, California • Orange, California • Palo Alto, California + 7 more
Conditions
Hepatocellular Carcinoma
Interventions
BBI608, BBI503, Sorafenib
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
29
States / cities
Gilbert, Arizona • Phoenix, Arizona • Coronado, California + 25 more
Conditions
Carcinoma, Renal Cell
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
31
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 27 more
Conditions
Advanced Cancer
Interventions
Bevacizumab, Sorafenib, Erlotinib, Trastuzumab, Lapatinib, Sunitinib, Cetuximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
sorafenib
Drug
Lead sponsor
Suleiman Massarweh
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
558
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 356 more
Conditions
Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma, WHO Grade III Glioma
Interventions
sorafenib tosylate, valproic acid, sildenafil citrate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

NCT00536575
Conditions
Multiple Myeloma
Interventions
Bortezomib, Sorafenib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Many Locations, Alabama • Many Locations, Arizona • Many Locations, Arkansas + 34 more
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Sorafenib+YIV-906, Sorafenib+placebo
Drug
Lead sponsor
Yiviva Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Flushing, New York • Lake Success, New York • New York, New York + 1 more
Conditions
Breast Cancer
Interventions
paclitaxel, sorafenib tosylate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Breast Cancer, Brain Metastases
Interventions
Whole Brain Radiotherapy (WBRT), Sorafenib
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Prostate Cancer
Interventions
Sorafenib, Placebo
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Conventional Surgery, Laboratory Biomarker Analysis, Sorafenib Tosylate, Temsirolimus
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
190
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Hartford, Connecticut + 118 more
Conditions
Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma, Stage III Malignant Mesothelioma, Stage IV Malignant Mesothelioma
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
18
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 14 more
Conditions
Lung Cancer
Interventions
Erlotinib, AZD6244, MK-2206, Sorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Houston, Texas
Conditions
Hepatocellular Carcinoma, Liver Cancer, HCC
Interventions
JX-594 recombinant vaccina GM-CSF, Best Supportive Care
Biological · Other
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
La Jolla, California • Orange, California • San Francisco, California + 8 more
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Erlotinib, Sorafenib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Palm Springs, California • New York, New York
Conditions
Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Placebo, Sorafenib Tosylate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
218
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 175 more
Conditions
Thyroid Cancer
Interventions
Temsirolimus and Sorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more